NRG Therapeutics has raised $67 million in financing from investors including the venture arms of Merck KGaA and Novartis to advance its mitochondrial-targeted drug aimed at neurodegenerative diseases such as Parkinson’s and ALS. The biotech plans to begin clinical testing of its lead candidate next year. This funding round reflects growing interest in mitochondrial pathways as therapeutic targets in challenging neurodegenerative conditions.